Surgery versus intra-lesional sclerosis with polidocanol (Aetoxisclerol) in labial venous malformations in children and adults: a randomized controlled trial - SASOV

Start Date01 Jan 2027

Sponsor / Collaborator

Centre Hospitalier Regional Universitaire De Tours

NCT07793630

/ Active, not recruitingPhase 4IIT

Comparison Between Isolated Foam Sclerotherapy and Foam Sclerotherapy Combined With Transdermal Laser for the Treatment of Reticular Veins and Telangiectasias: A Prospective Randomized Clinical Trial

his prospective, randomized, controlled, intraindividual split-leg clinical trial will compare isolated polidocanol foam sclerotherapy with the Laser After Foam (LAAF) technique for the treatment of reticular veins and telangiectasias of the lower limbs. The study will include 70 women aged 18 to 60 years with bilateral CEAP C1 telangiectasias and/or reticular veins. Each participant will receive LAAF in one lower limb and isolated foam sclerotherapy in the contralateral limb, with treatment laterality determined by randomization. The study will evaluate vascular clearance, residual vascular area, hyperpigmentation, retained thrombi and need for drainage, pain, adverse events, aesthetic improvement, patient satisfaction, and quality of life during follow-up through 180 days.

Start Date01 Sep 2026

Sponsor / Collaborator

University of Sao Paulo

ChiCTR2600129506

/ Not yet recruitingIIT

Efficacy and safety comparison of endoscopic ultrasound-guided lauromacrogol ablation versus saline lavage followed by paclitaxel and gemcitabine injection for the treatment of pancreatic cystic neoplasms: A multicenter, non-inferiority, single-blind, randomized controlled trial

Start Date15 Aug 2026

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

100 Clinical Results associated with Polidocanol

100 Translational Medicine associated with Polidocanol

100 Patents (Medical) associated with Polidocanol

1,217

Literatures (Medical) associated with Polidocanol

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Polidocanol augments high-intensity focused ultrasound efficacy for hyperintense fibroids on T2WI: a retrospective cohort study

Review

Author: He, Tian-wen ; He, Hong-ni ; Tang, Ying ; Lin, Chuan ; Tian, Ling ; Hu, Hui-quan ; Li, Jun ; Xia, Yu ; Yang, Ming-tao

OBJECTIVE:

To compare the immediate efficacy and safety of high-intensity focused ultrasound (HIFU) monotherapy with the combination of ultrasound-guided intratumoral polidocanol injection and HIFU for the treatment of uterine fibroids with high T2-weighted imaging (T2WI) signal intensity.

METHODS:

In this retrospective study, 116 patients with T2-hyperintense uterine fibroids treated between January 2024 and May 2025 were enrolled. Patients were allocated to either HIFU monotherapy (the H group, n = 63) or combined polidocanol and HIFU therapy (the H + P group, n = 53). Thereafter, therapeutic parameters, the non-perfused volume ratio (NPVR), and adverse events were compared between the two groups after propensity score matching.

RESULTS:

The matched cohort comprised 53 patients per group. The median NPVR was significantly higher in the H + P group than in the H group (92.57% vs. 77.81%, p < 0.001). Additionally, a significantly greater proportion of patients in the H + P group achieved an NPVR ≥ 80% (87% vs. 43%, p < 0.001) and an NPVR ≥ 90% (60% vs. 9%, p < 0.001). The H + P group also required significantly less sonication time and lower total energy delivery (both p < 0.05). Furthermore, the overall incidence of adverse events was similar between the two groups (73.6% vs. 69.8%, p = 0.506). However, the H + P group exhibited a markedly lower incidence of sacrococcygeal pain (5.7% vs. 45.3%, p < 0.001).

CONCLUSION:

Pretreatment with ultrasound-guided intratumoral polidocanol injection may improve the immediate ablation efficacy of HIFU in T2-hyperintense uterine fibroids, reducing energy requirements and mitigating procedure-related sacrococcygeal pain. These findings highlight the potential of this combined therapy and underscore the need for prospective studies to confirm its long-term clinical benefits.

01 Oct 2026·JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Endovascular Embolization of Left-Sided Varicocele: Outcomes by Venographic Anatomy and Coil-Adjunct Strategy

Article

Author: Tuna, Hüseyin Saygın ; Küçükay, Fahrettin

PURPOSE:

To evaluate outcomes after endovascular embolization for left-sided varicocele, with attention to venographic anatomy and embolic agent selection.

MATERIALS AND METHODS:

This retrospective single-center cohort included 46 men treated by endovascular embolization for symptomatic isolated left-sided varicocele between May 2018 and September 2025. The median age was 27 years (interquartile range [IQR], 22-32 years), and the median follow-up was 35 months (IQR, 22.5-70.0 months). Color Doppler ultrasound (US) confirmed pathologic reflux (>2 seconds during Valsalva). Venographic anatomy was classified using a 5-category scheme (Types 1-5) adapted from Jargiełło et al (Acta Radiol 2014; 56:63). Two embolic strategies were applied at operator discretion within a uniform distal-to-proximal protocol: distal coils plus proximal n-butyl cyanoacrylate glue vs distal coils plus proximal polidocanol foam. The primary outcome was recurrence (clinical and/or color Doppler ultrasound [US] defined); secondary outcomes were technical success, clinical success, and adverse events (Society of Interventional Radiology [SIR]/Baerlocher classification).

RESULTS:

Technical success was 100% and clinical success was 97.8% (45/46). One recurrence (2.2%) required reintervention. Minor adverse events occurred in 2 of 46 patients (4.3%); no major adverse events occurred. Complex anatomy (Types 3-5) was present in 56.5%. In exploratory comparisons, clinical success was 94.7% with coil + glue vs 100% with coil + polidocanol (P = .41); recurrence and adverse event rates did not differ significantly by embolic strategy or anatomic complexity. The very low event rate precluded meaningful assessment of equivalence.

CONCLUSIONS:

Endovascular embolization for left-sided varicocele achieved high technical and clinical success with low recurrence, including in patients with complex anatomy and prior surgical varicocelectomy. The absence of detectable between-group differences should not be interpreted as equivalence.

01 Sep 2026·Journal of Vascular Surgery-Venous and Lymphatic Disorders

Direct transvaginal ultrasound-guided sclerotherapy for pelvic venous disease

Article

Author: Leal Lorenzo, Jose Ignacio ; Cárdenas, Regina ; Alonso-Burgos, Alberto ; Hipola, Jose Maria ; Pillado, Eugenia

OBJECTIVE:

To report feasibility, safety, and clinical outcomes of direct transvaginal ultrasound (TVUS)-guided foam sclerotherapy for isolated periuterine/pericervical varices or residual venous reservoirs after prior embolization.

METHODS:

Prospective single-center observational cohort including consecutive women (January 2023-October 2025) meeting predefined inclusion and exclusion criteria. Procedures were performed under general anesthesia using ultrasound-guided transvaginal venous puncture with fluoroscopic confirmation. Low-nitrogen 3% polidocanol foam was injected directly into the targeted periuterine and pericervical venous plexuses until complete filling of the treated reservoirs was achieved. Primary end points were technical success and changes in the Pelvic Venous Clinical Severity Score (PVCSS) and Pelvic Varicose Vein Questionnaire (PVVQ) score at 1 month and 1 year. Normality was evaluated with the Shapiro-Wilk test, repeated-measures analysis of variance with Mauchly's test for sphericity, and Tukey's honestly significant difference for pairwise comparisons (α = 0.05). Institutional review board approval was obtained, and informed consent was required.

RESULTS:

Twenty-three patients (mean age, 40.5 years) underwent treatment; 74% had a history of prior gonadal vein embolization and presented with persistent symptoms at inclusion, whereas 26% had no prior embolization and presented with isolated periuterine or pericervical varices without axial reflux. Technical success was 100%. The mean procedural time was 36.0 ± 12.5 minutes, and the mean fluoroscopy time was approximately 1 minute. The mean sclerosant volume was 18.5 ± 5.3 mL. Radiation exposure remained low, with a mean dose-area product of 1.945 ± 0.347 Gy cm² and a mean absorbed dose of 72.0 ± 3.1 mGy. All patients were discharged the same day and resumed normal activities the following day. Minor vaginal bleeding occurred in 82% the day after treatment; no menstrual disturbances were reported. TVUS follow-up showed complete closure of the treated periuterine and pericervical venous plexuses, without evidence of recanalization in any patient at follow-up. The PVCSS improved from 12.91 at baseline to 7.87 (1 month) and 7.96 (1 year); the PVVQ score improved from 75.97 to 46.12 and 50.32, respectively. Overall improvement was significant (P < .001). Tukey's honestly significant difference confirmed decreases from baseline to 1 month and 1 year for both scales (PVCSS, P < .001; PVVQ, P < .003); the 1-month vs 1-year differences were not significant (PVCSS, P = .987; PVVQ, P = .094).

CONCLUSIONS:

Direct TVUS-guided 3% polidocanol foam sclerotherapy achieved high technical success, as well as significant and durable symptom improvement at 1 year in this small, highly selected cohort, with no major complications or recanalization. The technique offers a minimally invasive, targeted option for periuterine and pericervical venous reservoirs, particularly in cases not amenable to conventional endovascular access.

News (Medical) associated with Polidocanol

31 Aug 2026

·www.biospace.com

Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101

10XB-101 is a Novel Potential Best-in-Class Injectable Drug Being Developed for Focal Fat Reduction and Body Contouring Second Major Regional Licensing and Strategic Investment Agreement in 2026; Further Validates 10XB-101 Global Commercial Market Potential LA JOLLA, Calif., Aug. 30, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics (“Leios” or “The Company”), a clinical-stage biotechnology company focused on innovative aesthetic therapies, today announced an exclusive licensing agreement for 10XB-101, a proprietary injectable therapy containing polidocanol, and a related strategic equity investment, by subsidiaries of China Medical System Holdings Limited (“CMS”) (Hong Kong Stock Code: 867, Singapore Stock Code: 8A8), an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. “The agreement with CMS represents an important strategic milestone for Leios Therapeutics, validating our market-by-market commercialization model and the scientific promise of 10XB-101,” said Ted White, Chief Executive Officer of Leios Therapeutics. “CMS is an established pharmaceutical company with growing international activities, and this partnership will enable us to reach one of the world’s largest markets. Their decision to license 10XB-101 following a rigorous diligence process underscores the strength of our clinical data and commercial potential. Together with CMS, we look forward to accelerating development and expanding access to 10XB-101 in China. We are progressing our trial initiation activities and expect to commence the trial in early 2027.” This is the second major licensing and investment agreement signed in 2026 for the Company, and follows its partnership with BNC Korea. Together, the agreements establish Leios's presence in two of the most important markets for cosmetic procedures and skin care innovation outside the United States. South Korea serves as the global trendsetter in aesthetics, while China represents the volume powerhouse. Under the licensing agreement, CMS receives exclusive rights to develop, manufacture and commercialize 10XB-101 in mainland China (including Hong Kong and Macau). Leios will receive an upfront payment, regulatory and commercial milestone payments, and royalties on future net sales, and will support the advancement of its 10XB-101 clinical development program. In a separate transaction, CMS agreed to make a strategic equity investment in Leios. In its Phase 2b study in submental fat reduction, 10XB-101 demonstrated compelling efficacy, with 64% and 70% of completers in the higher dose groups (3.0% and 4.5%) achieving a grade 2 or greater improvement on both the clinician-reported and patient-reported submental fat scales (CSFS and PSFS), compared to 0% on placebo. Importantly, 10XB-101 demonstrated a clean safety pro the study 1 . Trial initiation activities are well underway, and the Company expects to commence the trial in early 2027. Vault Advisors acted as the exclusive financial advisor to Leios Therapeutics for this transaction. About 10XB-101 10XB-101 is being developed as a best-in-class minimally invasive injectable treatment designed to reduce focal fat deposits and enhance body contouring outcomes. Its active ingredient, polidocanol, is a synthetic, non-ionic detergent that induces targeted adipolysis: following injection in a defined pattern, it disrupts fat cell membranes, allowing the destroyed cells to be naturally absorbed by the body. Leios has completed Phase 2 trials in the submental fat reduction indication. About Leios Therapeutics Leios Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for aesthetic indications. The company's mission is to deliver scientifically differentiated products that offer meaningful benefits to patients, healthcare providers and partners. For more information, please visit . About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, CMS enables each medicine to fully realize both its clinical value and commercial value. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for CMS’s high-quality, sustainable development. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the development, regulatory approval, manufacturing and commercialization of 10XB-101; the timing, design and initiation of future clinical trials, including a potential Phase 3 clinical trial; future interactions with and decisions by regulatory authorities; the potential benefits and commercial opportunity of 10XB-101; the expected benefits of Leios’s agreements with CMS and its affiliates; and the potential receipt of milestone payments and royalties. Forward-looking statements are based on Leios’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the outcomes and timing of clinical trials and regulatory interactions; the ability to obtain and maintain regulatory approvals; the safety and efficacy of 10XB-101; the ability of Leios and its partners to perform their respective obligations; manufacturing and commercialization risks; market acceptance and competition; and other risks inherent in the development and commercialization of pharmaceutical products. Forward-looking statements speak only as of the date of this press release. Leios undertakes no obligation to update any forward-looking statement, except as required by applicable law. FOR MORE INFORMATION, PLEASE CONTACT: Ryan Kelly rkelly@leiostherapeutics.com ___________________________________________________________ 1 Data on file

Phase 2License out/inClinical Result

25 Aug 2026

·www.biospace.com

Olympia Pharmaceuticals Introduces Polidocanol 2% Injection for Targeted Cosmetic Vein Treatment

New injection gives healthcare providers a comfortable, effective option for cosmetic spider and reticular vein therapies ORLANDO, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a premier FDA-registered 503B outsourcing facility and 503A pharmacy, today announced the launch of its new Polidocanol 2% (20 mg/mL) injection . Expanding Olympia’s suite of specialized vein care offerings, this injection provides qualified healthcare professionals with a formulation that gently damages the vein lining, causing the vessel to collapse and gradually be reabsorbed by the body. Supplied in a 30 mL volume for intravenous (IV) administration, Polidocanol has local anesthetic properties that help ensure a comfortable treatment experience for patients. Known for its excellent tolerability, the formulation presents clinicians with a viable option for cosmetic vein treatment. “As we continue to expand our portfolio, we’re focused on anticipating what providers need to deliver efficient, high-quality care,” said Joshua Fritzler, President of Olympia Pharmaceuticals. “Adding Polidocanol gives practices another specialized option from a pharmacy partner they can rely on as they grow their aesthetic and vein care offerings.” Intended strictly for administration by qualified healthcare professionals, Polidocanol offers a ready-to-use formulation that streamlines procedure prep time. The 2% concentration (20 mg/mL) allows clinicians to maintain standardized protocols during routine aesthetic appointments. "Targeted vein care requires precision, and having a consistent formulation is critical for clinical protocols," said Dr. Christopher Lorich, PharmD, Pharmacist at Olympia Pharmaceuticals. "Polidocanol's dual action as a non-ionic detergent sclerosant and local numbing agent gives providers a dependable option that fits seamlessly into existing dermatology and cosmetic vein care." The new Polidocanol 2% injection is now available to order across 49 states for clinical office use. "As demand for minimally invasive cosmetic treatments continues to rise, practices are searching for dependable pharmacy partners who can supply trusted compounded formulations," said Hayden Goldman, Director of Commercial Sales at Olympia Pharmaceuticals. "Adding Polidocanol to our nationwide catalog reinforces our commitment to supporting medical aesthetics and dermatology providers with the therapies they need most." The addition of Polidocanol reflects Olympia’s broader strategy to expand its specialized clinical protocols, giving providers access to a diverse range of high-quality compounded therapies under one roof. With streamlined ordering processes and strict adherence to FDA quality standards, the company continues to bolster healthcare practices with dependable, ready-to-use aesthetic and vascular care solutions nationwide. For more information about Olympia Pharmaceuticals, visit olympiapharmacy.com or call 407-673-2222. About Olympia Pharmaceuticals Olympia Pharmaceuticals is a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility and 503A pharmacy supporting both patient-specific and office-use needs across the U.S. Co-founded by Stan and Naomi Loomis, the team is made up of pharmacy technicians, pharmacists, quality personnel, and engineers, creating an educated and experienced staff knowledgeable in all facets of pharmacy production. As an FDA-registered outsourcing facility, Olympia offers compounded medications to 49 states for both office use and patient prescriptions. Olympia specializes in weight loss, dermatology, IV nutritional therapy, erectile dysfunction, and more. Media Contact Daniele Spring Uproar by Moburst for Olympia Pharmaceuticals Daniele.Spring@Moburst.com

12 Aug 2026

·www.einpresswire.com

AMS Vascular Launches New Website to Expand Access to Vein Care Information

New website helps Greater Philadelphia patients recognize vein disease symptoms, understand the evaluation process, and explore minimally invasive treatments. Healthier legs begin with better information. Our new website gives patients the clarity and confidence to understand their symptoms and take the next step.” — Noah Rosen, MD, MBA, Board-Certified Vascular Surgeon HORSHAM, PA, UNITED STATES, August 12, 2026 / EINPresswire.com / -- AMS Vascular has launched a new patient-focused website designed to help people across Greater Philadelphia recognize common signs of vein disease, understand how specialists evaluate leg symptoms and explore treatment options before scheduling care. The new website brings symptom education, an online vein quiz, insurance information, treatment explanations and a simple way to submit a consultation request together in one place. It also helps patients understand when leg swelling, heaviness, aching, cramping, itching, burning, visible veins, skin discoloration or slow-healing wounds may be associated with an underlying vein condition and warrant a professional evaluation. "Many people live with uncomfortable leg symptoms for a long time because they are not sure what is causing them or where to begin," said Bruce D. Klugherz, MD, a board-certified interventional cardiologist with AMS Vascular. "We wanted the new website to give patients clear, useful information and a straightforward path to having their concerns properly evaluated." The website explains chronic venous insufficiency, a condition that can develop when valves in the leg veins do not work effectively. This can allow blood to pool in the legs and contribute to swelling, heaviness, aching, skin changes and other symptoms. Because these symptoms can have more than one cause, the site emphasizes the importance of an individualized clinical evaluation. Patients can also review the practice's evaluation process before their first visit. The process begins with a consultation focused on symptoms, medical history and treatment goals. A same-day ultrasound may then help the clinical team identify the source of the symptoms and develop a treatment plan based on the patient's diagnosis and needs. Clear Information About Modern Vein Treatment The website provides plain-language information about minimally invasive vein treatments available through AMS Vascular, including radiofrequency ablation, Varithena treatment and microphlebectomy. Radiofrequency ablation uses controlled heat to close a diseased vein. Varithena uses polidocanol injectable foam to treat certain affected veins. Microphlebectomy removes bulging surface varicose veins through very small incisions under local anesthesia. The most appropriate option depends on the patient's ultrasound findings, medical history and individual treatment goals. AMS Vascular's clinical team includes Noah Rosen, MD, MBA, a board-certified vascular surgeon with more than 20 years of experience treating venous and arterial disease, and Dr. Klugherz, who specializes in coronary, peripheral arterial and venous disease, and structural heart procedures. The practice provides care at its Horsham vein clinic , located within the AMS Cardiology Horsham office at 507 Prudential Road, Horsham, PA 19044. The practice accepts most major insurance plans and encourages patients to confirm their individual coverage when scheduling. Patients can call 215-371-3149 or visit https://amsvein.com/ to learn more and submit a consultation request. About AMS Vascular AMS Vascular is a vein treatment practice serving patients across Greater Philadelphia from its Horsham, Pennsylvania location. Its board-certified specialists evaluate and treat varicose veins, spider veins, chronic venous insufficiency and other vein-related conditions using individualized care plans and minimally invasive procedures. AMS Vascular is located within the AMS Cardiology Horsham office. Learn more at https://amsvein.com/ . Noah Rosen, MD MBA AMS Vascular +1 215-371-3149 Kaitlyn.Lantry@atriahealth.co Visit us on social media: Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Polidocanol

External Link

KEGG	Wiki	ATC	Drug Bank
D01539	Polidocanol	C05BB02	DB06811

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
primary varicose veins	Japan	Kaigen Pharma Co., Ltd.	26 Jul 2006
Varicose Veins	Australia	Accelagen	27 Jul 2001
Bleeding esophageal varices	Japan	Kaigen Pharma Co., Ltd.	28 Jun 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Venous Insufficiency	Phase 3	United States	Boston Scientific Corp.	01 Sep 2010
Telangiectasis	Phase 3	Germany	Chemische Fabrik Kreussler & Co. GmbH	08 Nov 2006
Vein disorder	Phase 3	Germany	Chemische Fabrik Kreussler & Co. GmbH	08 Nov 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05312970 (VERITAS, CTgov)	Phase 4	Varicose Veins	43	Varithena® (Varithena®)	lwixawexiz(stnydyuszq) = qqkqgjnlmz yjfdbwwfom (napdnyakjn, 8.23) View more	-	20 Mar 2026
				FDA-approved Endothermal Ablation (ETA) systems (FDA-approved ETA Systems)	lwixawexiz(stnydyuszq) = vegycaelta yjfdbwwfom (napdnyakjn, 4.55) View more
NCT02557542 (OSVeC, CTgov)	Not Applicable	Varicose Veins	3	Endovenous laser ablation+Sodium Tetradecyl+Polidocanol (One Stop Vein Clinic)	nyybvbqxig(tqzigaexyc) = wkqkcnvgoe ffrlheawyl (xpteaswuee, pliyrietzg - mqyhgozvlo) View more	-	16 May 2025
				Endovenous laser ablation+Sodium Tetradecyl+Polidocanol (Normal Care Pathway)	nyybvbqxig(tqzigaexyc) = ceykluapro ffrlheawyl (xpteaswuee, kpdjnbfnfi - zdtmcrddur) View more
NCT05154955 (NEWS)	Phase 2	-	-	聚多卡醇-10XB101	zqhsgbmgke(zbcqcpimku) = wamyhpwkzd qfxswussdr (chkgchxulv )	Positive	11 Mar 2024
				安慰剂	zqhsgbmgke(zbcqcpimku) = ilvyyyrfue qfxswussdr (chkgchxulv )
UEGW2022	Not Applicable	Hemorrhoids	46	Polidocanol foam sclerotherapy (SP)	lrhevbezba(hletgcrbvf) = izsvcpygya xoeusssroa (fjidksaldr ) View more	Positive	09 Oct 2022
				Polidocanol foam (Hemorrhoidal artery ligation with recto-anal repair (HAL-RAR))	lrhevbezba(hletgcrbvf) = cefevgrqtf xoeusssroa (fjidksaldr ) View more
NCT03791775 (SCLEROFOAM, Pubmed \| Tech Coloproctol) Manual	Phase 2	Hemorrhoids	183	polidocanol foam	acgsmpmxtp(kkuwfftlza) = tlvvfcskit uxfmxoyjzj (mynyvmhpbc ) View more	Positive	25 Mar 2022
NCT02462720 (COMFORT, CTgov)	Phase 4	Pain \| Varicose Veins	35	polidocanol (Varithena®)	tlcgenwuvx(xwqobafakj) = idobyutprz gckyvyivab (wxftnpvaud, 2.90) View more	-	23 Jan 2018
				Varithena (Radiofrequency Ablation)	tlcgenwuvx(xwqobafakj) = gxgzkapgnl gckyvyivab (wxftnpvaud, 2.90) View more
NCT02657252 (PG3T, CTgov)	Phase 4	Telangiectasis \| Varicose Veins	115	Glucose (Glucose)	ofubwhnzxy(izdlfihyud) = gelewejtvi uwntmqtnbp (vlqfkgcbsv, 22.69) View more	-	28 Nov 2017
				Glucose (Polidocanol With Glucose)	ofubwhnzxy(izdlfihyud) = uyzizhzxta uwntmqtnbp (vlqfkgcbsv, 18.63) View more
NCT00758420 (Pubmed \| Phlebology)	Phase 2/3	Varicose Veins	77	Varithena 1%	yzlerchlqf(plytgezalk) = reported as mild and generally resolved without sequelae sdodavfuol (qzvvrfeboh )	-	01 Apr 2017
				Placebo
NCT02054325 (CTgov)	Phase 4	Vein disorder \| Varicose Veins	106	Polidocanol with Glucose (Polidocanol With Glucose)	epyqyxknku(xhlygifkxm) = zmziwtkuel keckcjbakz (gundviylyd, 9.09) View more	-	27 Jan 2017
				Glucose (Glucose)	epyqyxknku(xhlygifkxm) = jftjrpcyzv keckcjbakz (gundviylyd, 17.04) View more
NCT01072877 (VANISH-1, CTgov)	Phase 3	Varicose Veins	279	Placebo Vehicle (Vehicle)	zfcyljbqec(xzcyvvcnji) = kmwcdumbks gpplnpmueh (gokwypkjlu, 0.452) View more	-	16 May 2014
				Polidocanol injectable foam (PEM) (Polidocanol Injectable Foam 0.125%)	zfcyljbqec(xzcyvvcnji) = mxxefvioea gpplnpmueh (gokwypkjlu, 0.447) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis